key: cord-0955711-jljhvfh1
authors: nan
title: 武汉地区重型及危重型2019新型冠状病毒肺炎（COVID-19）患者D-二聚体、炎症指标、细胞因子与疾病严重程度的关系
date: 2020-11-03
journal: Zhonghua Xue Ye Xue Za Zhi
DOI: 10.3760/cma.j.issn.0253-2727.2020.11.008
sha: 5f4ffbad6ee6177ea580aa70706ca0244885a940
doc_id: 955711
cord_uid: jljhvfh1

OBJECTIVE: To analyze the association of D-dimer levels, inflammatory indicators, cytokine abnormality, and disease severity in COVID-19 severe/critical type patients. METHODS: The medical records of 41 patients were collected from a single center in Wuhan from February 8, 2020 to March 25, 2020. The patients were divided into severe type group (28 patients) and critical type group (13 patients). The levels of D-dimer, WBC, ANC, PCT, hsCRP, IL-2R, IL-6, IL-8, and TNF-α were compared among patients with different clinical types of COVID-19 infection. Moreover, the changes in the cytokines were analyzed in patients with different D-dimer levels. And, the levels of D-dimer, IL-2R, IL-6, IL-8, and TNF-α before and after anticoagulant therapy were assessed. Statistical analyses were performed using Student t test, Mann-Whitney U test, and Chi-square test. RESULTS: Among the 41 patients, 23 were men (56.1%) and 18 were women (43.9%); the median patient age was 57 y. The age of the critical type patients [(61.1±10.4) y] was higher than that of severe type patients [(52.8±11.7) y]; the difference was significant (t=−2.264, P=0.032). The proportion of critical type patients with chronic diseases, especially hypertension, cardiovascular disease, and cerebrovascular disease, was higher as compared to that in those with severe type patients; the differences were significant (all P<0.05). The prevalence of dyspnea, sweats, and fatigue symptoms in the critical type patients was higher than that in those with severe type disease; the differences were significant (χ(2)=14.898, 6.972, 7.823; P<0.001, 0.008, 0.005). The levels of D-dimer, WBC, ANC, PCT, hsCRP, and IL-8 in critical type patients were higher than those in severe type patients; the differences were significant (all P<0.05). The levels of IL-2R, IL-8, and TNF-α in patients with abnormal D-dimer were higher as compared to those in patients with normal D-dimer levels; the differences were significant (all P<0.05). Eight patients were treated with prophylactic anticoagulation; the levels of D-dimer, IL-2R, IL-6 and IL-8 after anticoagulant therapy were lower than those before treatment. CONCLUSION: COVID-19 critical type patients have more serious coagulation-immune dysfunction and dynamic monitoring of D-dimer and cytokines levels helps in identifying critical type patients as early as possible; anticoagulant therapy may improve the patient's condition by correcting coagulation-immune dysfunction.

【Abstract】 Objective To analyze the association of D-dimer levels, inflammatory indicators, cytokine abnormality, and disease severity in COVID-19 severe/critical type patients. Methods The medical records of 41 patients were collected from a single center in Wuhan from February 8, 2020 to March 25, 2020. The patients were divided into severe type group(28 patients)and critical type group(13 patients) . The levels of D-dimer, WBC, ANC, PCT, hsCRP, IL-2R, IL-6, IL-8, and TNF-α were compared among patients with different clinical types of COVID-19 infection. Moreover, the changes in the cytokines were analyzed in patients with different D-dimer levels. And, the levels of D-dimer, IL-2R, IL-6, IL-8, and TNF-α before and after anticoagulant therapy were assessed. Statistical analyses were performed using Student t test, Mann-Whitney U test, and Chi-square test. Results Among the 41 patients, 23 were men (56.1％)and 18 were women(43.9％) ; the median patient age was 57 y. The age of the critical type patients［ (61.1±10.4)y］was higher than that of severe type patients［ (52.8±11.7)y］ ; the difference was significant(t＝-2.264, P＝0.032) . The proportion of critical type patients with chronic diseases, especially hypertension, cardiovascular disease, and cerebrovascular disease, was higher as compared to that in those with severe type patients; the differences were significant (all P＜0.05) . The prevalence of dyspnea, sweats, and fatigue symptoms in the critical type patients was higher than that in those with severe type disease; the differences were significant(χ 2 ＝14.898, 6.972, 7.823; P＜0.001, 0.008, 0.005) . The levels of D-dimer, WBC, ANC, PCT, hsCRP, and IL-8 in critical type patients were higher than those in severe type patients; the differences were significant(all P＜0.05) . The levels of IL-2R, IL-8, and TNF-α in patients with abnormal D-dimer were higher as compared to those in patients with normal D-dimer levels; the differences were significant(all P＜0.05) . Eight patients were treated with prophylactic anticoagulation; the levels of D-dimer, IL-2R, IL-6 and IL-8 after anticoagulant therapy were lower than those before treatment. Conclusions COVID-19 critical type patients have more serious coagulation-immune dysfunction and dynamic monitoring of D-dimer and cytokines levels helps in identifying critical type patients as early as possible; anticoagulant therapy may improve the patient's condition by correcting coagulation-immune dysfunction.

【Key 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19) 患者出凝血功能 障碍病因分析及诊治策略 ［J］ . 中华血液学杂志

Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019［J］ . medRxiv

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province［J］

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019(COVID-19) : A Review［J］

COVID-19 with Different Severities: A Multicenter Study of Clinical Features［J］

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia［J］

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study［J］

The immunopathogenesis of sepsis［J］

Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation ［J］

Thrombosis as an intravascular effector of innate immunity［J］

ANCrophil extracellular traps in COVID-19［J］

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19